Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium
November 19 2021 - 9:00AM
Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology
company developing small molecule and immunotherapy treatments to
transform care for breast and gynecological cancers, today
announced clinical data on onapristone extended release (ONA-XR)
will be presented at the 2021 San Antonio Breast Cancer Symposium
(SABCS) taking place virtually and in San Antonio, Texas, from
December 7-10, 2021.
“We are pleased that ONA-XR data from multiple stages of breast
cancer will be presented at SABCS including the first clinical data
from the ONAWA trial, sponsored by the Spanish cancer research
group SOLTI, of ONA-XR in early-stage breast cancer and updates
from two ongoing clinical trials of ONA-XR in metastatic breast
cancer. We look forward to connecting with the oncology community
at SABCS, to discuss advancements in breast cancer and further
highlight the potential of ONA-XR to make a meaningful impact in
the lives of people living with breast cancer,” said Martin Lehr,
CEO of Context Therapeutics.
Details on the presentations are as follows:
Title: Primary results of ONAWA (SOLTI-1802) trial: A window of
opportunity trial of onapristone in postmenopausal women with
progesterone receptor-positive/HER2-negative early breast cancer
(EBC)Abstract: 511Session: Poster Session 1, Prognostic and
Predictive Factors: Predictive Biomarkers for Endocrine
TherapiesDate / time: Wednesday, December 8, 2021, 8-9:30 a.m. ET /
7-8:30 a.m. CTPresenter: Meritxell Bellet, M.D., Ph.D., SOLTI
Breast Cancer Research Group, Vall d’Hebron University Hospital,
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
Title: The SMILE study: A phase 2 trial of onapristone in
combination with fulvestrant for patients with ER+ and HER2-
metastatic breast cancer after progression on endocrine therapy and
CDK4/6 inhibitorsAbstract: 379Session: Ongoing Trials Poster
Sessions 2, Targeted therapy - antiprogestin onapristoneDate /
time: Thursday, December 9, 2021, 6-7:30 p.m. ET / 5-6:30 p.m.
CTPresenter: Sailaja Kamaraju, M.D., Medical College of Wisconsin,
Milwaukee, Wis., and Kari Wisinski, M.D., University of Wisconsin -
Madison
Title: Circulating tumor DNA-guided adaptive therapy escalation
in ER+ MBC: A phase 1b study with letrozole, palbociclib and
onapristone ERAbstract: 1538Session: Ongoing Trials Poster Session
2, Patient management - circulating tumor guided adaptive
therapyDate / time: Thursday, December 9, 2021, 6-7:30 p.m. ET /
5-6:30 p.m. CTPresenter: Joshua Drago, M.D., Pedram Razavi, M.D.,
Ph.D., and Komal Jhaveri, M.D., Memorial Sloan Kettering Cancer
Center
Details on the presentations listed above are also available on
the 2021 SABCS website:
https://www.sabcs.org/Program/Schedule-at-a-Glance.
About Onapristone Extended ReleaseONA-XR
(onapristone extended release) is a potent and specific antagonist
of the progesterone receptor (PR) that is orally administered.
Currently, there are no approved therapies that selectively target
PR+ cancers. Preliminary preclinical and clinical data suggest that
ONA-XR has anticancer activity by inhibiting progesterone receptor
binding to chromatin, downregulating cancer stem cell mobilization
and blocking immune evasion. ONA-XR is currently being evaluated in
three Phase 2 clinical trials and one Phase 1b/2 clinical trial in
PR+ breast, ovarian and endometrial cancers, as well as in two
Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR
is an investigational drug that has not been approved for marketing
by any regulatory authority.
About Context
Therapeutics®Context Therapeutics Inc.
(Nasdaq: CNTX), is a women’s oncology company developing small
molecule and immunotherapy treatments to transform care for breast
and gynecological cancers. The company’s robust clinical program
for lead candidate onapristone extended release (ONA-XR) comprises
three Phase 2 clinical trials and one Phase 1b/2 clinical trial in
hormone-driven breast, ovarian and endometrial cancer, as well as
two Phase 0 biomarker pharmacodynamic trials in breast cancer.
ONA-XR is a novel, first-in-class small molecule under development
as a complete antagonist of the progesterone receptor, a key
unchecked mechanism in hormone-driven women’s cancers. Context is
headquartered in Philadelphia, PA. For more information, visit
www.contexttherapeutics.com.
Forward-looking StatementsThis press release
contains “forward-looking statements” that involve substantial
risks and uncertainties for purposes of the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, included in
this press release regarding strategy, future operations,
prospects, plans and objectives of management, including words such
as "may," "will," "expect," "anticipate," "plan," "intend," and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
forward-looking statements. These include, without limitation,
statements regarding (i) the results of our clinical trials, (ii)
the potential benefits of the product candidates, (iii) the
likelihood data will support future development, and (iv) the
likelihood of obtaining regulatory approval of our product
candidates. Forward-looking statements in this release involve
substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by the
forward-looking statements, and we, therefore cannot assure you
that our plans, intentions, expectations or strategies will be
attained or achieved. Other factors that may cause actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in our filings with
the U.S. Securities and Exchange Commission, including the
section titled “Risk Factors” contained therein. Except as
otherwise required by law, we disclaim any intention or obligation
to update or revise any forward-looking statements, which speak
only as of the date they were made, whether as a result of new
information, future events or circumstances or otherwise.
Media Contact:Gina Cestari6
Degrees971-797-7904gcestari@6degreespr.com
Investor Relations Contact:Laine YonkerEdison
Grouplyonker@edisongroup.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From May 2024 to Jun 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Jun 2023 to Jun 2024